Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Masimo Ahead, But Philips Fights On In Long-Running Patent Battle

This article was originally published in The Gray Sheet

Executive Summary

A U.S. district court upheld an Oct. 2014 ruling finding Philips guilty of infringing two Masimo patents related to pulse oximetry technology, and awarded $467 million in damages, but Philips is appealing.

You may also be interested in...



Philips, Masimo Bury Hatchet Over Patient-Monitoring Battle

Philips and Masimo have put to rest their long legal wrangling over patient-monitoring technology patents and shaken hands on a multi-year, global sales, and marketing partnership.

QUOTED. 6 May 2020. Paul Diaz.

Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.

After ODAC: The State Of Accelerated Approval At The US FDA

US FDA’s Accelerated Approval process has always been a deceptively simple idea. After a three-day public review of ‘dangling’ applications, the underlying complexity remains.

Related Companies

UsernamePublicRestriction

Register

MT033943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel